Novocure outlines four-indication expansion and profitability target for 2027 as GBM growth continues
                    
                        Earnings Call Insights: Novocure Limited (NVCR) Q3 2025 Management View Executive Chairman William Doyle stated that Novocure is transitioning from a single indication company to a platform therapy company, with a focus on "preparing to treat 4 cancer...                    
                    
                         
                        
                            Seeking Alpha